These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
    Author: Demetri GD.
    Journal: Semin Oncol; 1996 Jun; 23(3 Suppl 6):22-6. PubMed ID: 8677444.
    Abstract:
    Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease. Attaining a clinical response can be a significant end point in sarcomas because such a response may allow function-sparing surgery or improved surgical resection of bulky primary tumors. Studies have shown that higher response rates can be obtained in sarcomas using dose-intensified chemotherapy than with conventional-dose chemotherapy. Although the early data using high-dose ifosfamide in the treatment of sarcomas are promising, the median durations of response have been less than 1 year. The continuing advances in supportive care technology will facilitate the ability to conduct large-scale trials in sarcomas using dose-intensified chemotherapy. The aim of these trials should be to optimize the dosing and antineoplastic efficacy of ifosfamide as a single agent and in combination regimens.
    [Abstract] [Full Text] [Related] [New Search]